Nov 30, 2022 04:30PM SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer

Nov 9, 2022 04:30PM SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates

Oct 3, 2022 06:46AM SQZ Biotechnologies (SQZ) Reports Preclinical Research Demonstrating AAC Platform's Potential

Oct 3, 2022 06:45AM SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy

Sep 6, 2022 04:33PM SQZ Biotechnologies (SQZ) Announces Leadership Transition

Sep 6, 2022 04:30PM SQZ Biotechnologies Announces Leadership Transition

Jun 21, 2022 06:45AM SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

May 18, 2022 06:45AM SQZ Biotechnologies (SQZ) Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

May 18, 2022 06:45AM SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

Apr 11, 2022 06:47AM SQZ Biotechnologies (SQZ) Reports New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

Apr 11, 2022 06:45AM SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

Apr 4, 2022 04:45PM SQZ Biotechnologies (SQZ) Publishes Preclinical Research on SQZ TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Apr 4, 2022 04:45PM SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Mar 8, 2022 04:45PM SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meet

Feb 15, 2022 05:16PM Form 4 SQZ Biotechnologies Co For: Feb 10 Filed by: BERNSTEIN HOWARD PHD MD

Feb 1, 2022 06:45AM SQZ Biotechnologies (SQZ) Reports Publication of Comprehensive Preclinical Research on SQZ APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activatio

Feb 1, 2022 06:45AM SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation

Nov 12, 2021 07:00AM SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting

Sep 13, 2021 06:46AM SQZ Biotechnologies (SQZ) Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier Platform

Sep 13, 2021 06:45AM SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

Jun 9, 2021 06:47AM SQZ Biotechnologies (SQZ) Tolerizing Antigen Carrier Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

Jun 9, 2021 06:45AM SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

Apr 27, 2021 04:30PM SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021

Apr 10, 2021 08:30AM SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KRAS Driven Tumors

Mar 10, 2021 04:45PM SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Feb 25, 2021 05:53PM Form 4 SQZ Biotechnologies Co For: Feb 23 Filed by: BERNSTEIN HOWARD PHD MD

Jan 27, 2021 06:45AM SQZ Biotechnologies Presents Preclinical Data for their SQZ Tolerizing Antigen Carrier Platform in Antigen-Specific Immune Tolerance (ASIT) Digital Summit Invited Talk

Oct 30, 2020 06:31PM Form 4 SQZ Biotechnologies Co For: Oct 29 Filed by: BERNSTEIN HOWARD PHD MD

Oct 29, 2020 08:47PM Form 3 SQZ Biotechnologies Co For: Oct 29 Filed by: BERNSTEIN HOWARD PHD MD